<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01747447</url>
  </required_header>
  <id_info>
    <org_study_id>2012P000560</org_study_id>
    <secondary_id>5R01AR060574-03</secondary_id>
    <nct_id>NCT01747447</nct_id>
  </id_info>
  <brief_title>VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture</brief_title>
  <acronym>VITAL</acronym>
  <official_title>VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in
      25,874 U.S. men and women investigating whether taking daily dietary supplements of vitamin
      D3 (2000 IU) or fish oil (1 gram of omega-3 fatty acids) reduces the risk of developing
      cancer, heart disease, and stroke in people who do not have a prior history of these
      illnesses. This ancillary study is being conducted among a sub-cohort of 771 participants in
      VITAL and will test the efficacy and safety of high-dose vitamin D supplementation vs.
      placebo on skeletal health and body composition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The VITAL: Effects on Bone Structure and Architecture is an ancillary study of the parent
      VITAL. This study has enrolled a sub-cohort of 771 VITAL participants at the NIH-sponsored
      Harvard Catalyst Clinical and Translational Science Center (CTSC). The following measurements
      will be performed at baseline and 2 years post-randomization to determine whether high-dose
      vitamin D supplementation vs. placebo: 1) produces small increases or reduces bone loss in
      spine, hip, and total body areal bone density as assessed by dual x-ray absorptiometry (DXA);
      2) reduces bone turnover as assessed by biomarkers of bone resorption and formation; 3)
      improves (a) volumetric bone mineral density (vBMD) and measures of bone structure as
      assessed by peripheral quantitative computed tomography (pQCT) and (b) bone microarchitecture
      as assessed by high resolution pQCT (HR-pQCT) at the distal radius and tibia as well as
      trabecular bone score (TBS) at the spine; and 4) results in changes in body composition as
      assessed by DXA. Parallel assessments of the effects of omega-3 fatty acids will be
      performed. This study may elucidate the mechanisms through which high-dose vitamin D may
      prevent age-related fractures and provide new insights into the role of vitamin D on skeletal
      health and body composition.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2012</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Bone density</measure>
    <time_frame>2 years</time_frame>
    <description>To determine whether vitamin D and/or fish oil supplementation produces small increases or reduces bone loss in spine, hip, and total body areal bone density, as assessed by DXA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Turnover</measure>
    <time_frame>2 years</time_frame>
    <description>To determine whether vitamin D and/or fish oil supplementation reduces bone turnover, as assessed biomarkers of bone resorption and bone formation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Structure</measure>
    <time_frame>2 years</time_frame>
    <description>To determine whether vitamin D and/or fish oil supplementation results in changes in bone structure.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Body Composition</measure>
    <time_frame>2 years</time_frame>
    <description>To determine whether vitamin D and/or fish oil supplementation results in changes in body composition as assessed by DXA: total body fat and lean mass, and fat mass index and lean mass index, regional fat and lean mass and derived ratios.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">771</enrollment>
  <condition>Bone Density</condition>
  <condition>Body Composition</condition>
  <condition>Bone Health</condition>
  <arm_group>
    <arm_group_label>Vitamin D placebo + fish oil placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D placebo + fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D + fish oil placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D + fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 placebo</intervention_name>
    <description>Vitamin D placebo</description>
    <arm_group_label>Vitamin D placebo + fish oil placebo</arm_group_label>
    <arm_group_label>Vitamin D placebo + fish oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil placebo</intervention_name>
    <description>Fish oil placebo</description>
    <arm_group_label>Vitamin D placebo + fish oil placebo</arm_group_label>
    <arm_group_label>Vitamin D + fish oil placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omega-3 fatty acids (fish oil)</intervention_name>
    <description>Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).</description>
    <arm_group_label>Vitamin D placebo + fish oil</arm_group_label>
    <arm_group_label>Vitamin D + fish oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 (cholecalciferol), 2000 IU per day.</description>
    <arm_group_label>Vitamin D + fish oil placebo</arm_group_label>
    <arm_group_label>Vitamin D + fish oil</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Participants in VITAL (NCT 01169259) who meet the following criteria are eligible to
        participate in this ancillary study:

          -  Those who are using bisphosphonates currently or within the past 2 years, or other
             bone-active medications currently or within the past year are not eligible for this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meryl S LeBoff, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vitalstudy.org/</url>
    <description>VITAL Study Website</description>
  </link>
  <reference>
    <citation>LeBoff MS, Yue AY, Copeland T, Cook NR, Buring JE, Manson JE. VITAL-Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega-3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA-3 TriaL (VITAL). Contemp Clin Trials. 2015 Mar;41:259-68. doi: 10.1016/j.cct.2015.01.007. Epub 2015 Jan 24.</citation>
    <PMID>25623291</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2012</study_first_submitted>
  <study_first_submitted_qc>December 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2012</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Meryl LeBoff</investigator_full_name>
    <investigator_title>Director of Skeletal Health and Osteoporosis Center</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

